Primer: Shanghai Ark Biopharmaceutical (SAB HK) - Aug 2026
Shanghai Ark Biopharmaceutical is a clinical-stage biopharmaceutical company with a strategic focus on developing and commercializing novel...
96 Views
ArkBio (爱科百发) Pre-IPO: PHIP Update Shows RSV on Track, IPF Bar Rises
ArkBio Pre-IPO: We look at its PHIP updates and further our analysis in competitive landscape analysis across RSV, IPF, and ADHD pipelines.
258 Views
ECM Weekly (22 September 2025)- Chery, Zijin Gold, Orion, Myungin, Urban, Avepoint, Dongfang
Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.
672 Views
ArkBio (爱科百发) Pre-IPO: Early Signs of Success for Recycled Assets
ArkBio seeks to raise at least $100 million through a Hong Kong listing, with JPM and CITIC as joint sponsors. We look at their core products, pre...
433 Views
Pre-IPO Shanghai Ark Biopharmaceutical - Insights on Pipeline and Related Concerns
The article mainly analyzed Ark Biopharmaceutical in terms of the important product candidates AK0529 (ziresovir) and AK3280 that entered the...
520 Views
No more insights